Biogen Inc (BIIB)


Stay up to date

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Financial Statements

Key Info

  • Industry: Biological Product (except Diagnostic) Manufacturing
  • Sector: Manufacturing
  • CEO Name: Michel Vounatsos

Key Statistics

  • Stock Price: $215.63
  • Dividend Yield: 0%
  • Market Capitalization: $31,344,148,873
  • Shares Outstanding: 145,360,798
  • Number of Employees: 13,414
  • Trailing 12-Month EPS: $7.97
  • Trailing 12-Month DPS: $0
  • Payout Ratio: 0.0%

Important Dates

  • Next Earnings Date: 2024-04-23
  • Next Ex-Dividend Date:

Price Trends

  • Current Stock Price: $215.63
  • 52-week high: $319.76
  • 52-week low: $211.02
  • 200-day moving average: $241.68
  • 50-day moving average: $221.51


  • 1-Month Price Return: -2.8%
  • 3-Month Price Return: -16.7%
  • 6-Month Price Return: -16.1%
  • 1-Year Price Return: -21.6%
  • 2-Year Price Return: 2.2%
  • 5-Year Price Return: -8.8%

Visit the Passiv Stock Directory

Data provided by IEX Cloud

For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast